Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tevogen Bio Holdings Inc. - Common Stock (NQ: TVGN ) 1.720 +0.340 (+24.64%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tevogen Bio Holdings Inc. - Common Stock < Previous 1 2 Next > Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days October 18, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow October 17, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion October 17, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality October 16, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions October 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for October 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections October 14, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 October 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID October 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation September 24, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation October 08, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Secures $6 Million Series C Preferred Stock Investment August 22, 2024 From Tevogen Bio Inc Via GlobeNewswire CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health August 14, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities August 09, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback July 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian July 10, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities June 26, 2024 From Tevogen Bio Inc Via GlobeNewswire Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility July 08, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances June 25, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference June 18, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Set to Join Russell 3000® Index June 12, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts June 11, 2024 From Tevogen Bio Inc Via GlobeNewswire CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event June 07, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports First Quarter 2024 Financial Results May 29, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives May 16, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives May 10, 2024 From Tevogen Bio Inc Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.